2. Academic Validation
  3. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

  • J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
Jingjing Wu 1,  Mingzhi Zhang 1,  Delong Liu 2
Affiliations

Affiliations

  • 1 Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • 2 Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Delong_liu@nymc.edu.
PMID: 26957112 DOI: 10.1186/s13045-016-0250-9
Abstract

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (Btk) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective Btk inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation Btk Inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.

Figures
Products